Menu
GWAS Study

Narcolepsy is strongly associated with the T-cell receptor alpha locus.

Hallmayer J, Faraco J, Lin L et al.

19412176 PubMed ID
GWAS Study Type
4042 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

HJ
Hallmayer J
FJ
Faraco J
LL
Lin L
HS
Hesselson S
WJ
Winkelmann J
KM
Kawashima M
MG
Mayer G
PG
Plazzi G
NS
Nevsimalova S
BP
Bourgin P
HS
Hong SC
HY
Honda Y
HM
Honda M
HB
Högl B
LW
Longstreth WT
MJ
Montplaisir J
KD
Kemlink D
EM
Einen M
CJ
Chen J
MS
Musone SL
AM
Akana M
MT
Miyagawa T
DJ
Duan J
DA
Desautels A
EC
Erhardt C
HP
Hesla PE
PF
Poli F
FB
Frauscher B
JJ
Jeong JH
LS
Lee SP
TT
Ton TG
KM
Kvale M
KL
Kolesar L
DM
Dobrovolná M
NG
Nepom GT
SD
Salomon D
WH
Wichmann HE
RG
Rouleau GA
GC
Gieger C
LD
Levinson DF
GP
Gejman PV
MT
Meitinger T
YT
Young T
PP
Peppard P
TK
Tokunaga K
KP
Kwok PY
RN
Risch N
ME
Mignot E
Chapter II

Abstract

Summary of the research findings

Narcolepsy with cataplexy, characterized by sleepiness and rapid onset into REM sleep, affects 1 in 2,000 individuals. Narcolepsy was first shown to be tightly associated with HLA-DR2 (ref. 3) and later sublocalized to DQB1*0602 (ref. 4). Following studies in dogs and mice, a 95% loss of hypocretin-producing cells in postmortem hypothalami from narcoleptic individuals was reported. Using genome-wide association (GWA) in Caucasians with replication in three ethnic groups, we found association between narcolepsy and polymorphisms in the TRA@ (T-cell receptor alpha) locus, with highest significance at rs1154155 (average allelic odds ratio 1.69, genotypic odds ratios 1.94 and 2.55, P < 10(-21), 1,830 cases, 2,164 controls). This is the first documented genetic involvement of the TRA@ locus, encoding the major receptor for HLA-peptide presentation, in any disease. It is still unclear how specific HLA alleles confer susceptibility to over 100 HLA-associated disorders; thus, narcolepsy will provide new insights on how HLA-TCR interactions contribute to organ-specific autoimmune targeting and may serve as a model for over 100 other HLA-associated disorders.

807 European ancestry cases, 1,074 European ancestry controls

Chapter III

Study Statistics

Key metrics and study information

4042
Total Participants
GWAS
Study Type
Yes
Replicated
363 European ancestry cases, 355 European ancestry controls, 133 African American cases, 144 African American controls, 561 Asian ancestry cases, 605 Asian ancestry controls
Replication Participants
European, African American or Afro-Caribbean, East Asian
Ancestry
U.S., Canada
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.